Lupin Q1 Review: Broad-Based Growth Impresses, But Systematix Sees US Competition Ahead

Revenue rose 32% YoY and Ebitda surged 50% in Q1 FY27, but Systematix remains cautious on Lupin's near-term US business outlook amid increasing competition in key products.